Short Interest in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Declines By 20.6%

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 1,852,420 shares, a decrease of 20.6% from the January 29th total of 2,333,055 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 711,535 shares, the short-interest ratio is currently 2.6 days. Based on an average trading volume of 711,535 shares, the short-interest ratio is currently 2.6 days. Currently, 0.3% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Jefferies Financial Group lowered Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $28.00.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently bought and sold shares of FMS. Morgan Stanley lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after acquiring an additional 942,497 shares in the last quarter. Bank of America Corp DE lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares in the last quarter. ABC Arbitrage SA boosted its stake in Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after purchasing an additional 229,589 shares during the period. Integral Health Asset Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after purchasing an additional 200,000 shares during the period. Finally, Pzena Investment Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after buying an additional 153,870 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

Shares of FMS opened at $23.47 on Monday. The business has a 50-day moving average of $23.30 and a 200 day moving average of $24.44. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46. The firm has a market cap of $13.60 billion, a P/E ratio of 12.29, a price-to-earnings-growth ratio of 0.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.92 and a current ratio of 1.26.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.67 by $0.16. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.